Condition Center

About two-thirds of older women fail to qualify for discontinuation of cervical cancer screening, according to a study published in Gynecologic Oncology. Jacqueline M. Mills, M.D., from the Boston University School of Medicine, and colleagues assessed eligibility for cervical cancer screening discontinuation based on current guidelines among 590,901 women aged 64 years old listed in a...

According to a study recently published in the Journal of Women’s Health, nearly three in four low-income women cite perceived substantial financial barriers to undergoing cervical cancer screening. Caitlin B. Biddell, from the University of North Carolina at Chapel Hill, and colleagues surveyed 702 low-income, uninsured, or publicly insured women (aged 25 to 64 years old)...

Global cervical cancer incidence and mortality rates have remained stable or are decreasing, according to a study published in Cancer. Shujuan Lin, from Zhejiang University School of Medicine in Hangzhou, China, and colleagues extracted data on global cervical cancer incidence and mortality in 2018 and analyzed their correlations with the Human Development Index. Temporal trends were...

Models predict that near elimination of cervical cancer will be reached earlier in low-poverty versus high-poverty counties in the United States, according to a study published in Cancer Epidemiology, Biomarkers & Prevention. Jennifer C. Spencer, Ph.D., from the Harvard T. H. Chan School of Public Health in Boston, and colleagues examined the effects of human papillomavirus...

For patients with persistent, recurrent, or metastatic cervical cancer who are receiving chemotherapy with or without bevacizumab, progression-free survival and overall survival are significantly longer with pembrolizumab versus placebo, according to a study published in the New England Journal of Medicine. Nicoletta Colombo, M.D., Ph.D., from the University of Milan-Bicocca and European Institute of Oncology IRCCS,...

According to a research letter published in JAMA Network Open, a substantial proportion of women who were not vaccinated for human papillomavirus (HPV) never received cervical cancer screening or were not up to date on screening recommendations in 2019. Kalyani Sonawane, Ph.D., from UTHealth School of Public Health in Houston, and colleagues used data from the...

Following the introduction of human papillomavirus (HPV) vaccination in England, there was a substantial reduction in cervical cancer and the incidence of grade 3 cervical intraepithelial neoplasia (CIN3), according to a study published in The Lancet. Milena Falcaro, Ph.D., from King’s College London, and colleagues used an extension of the age-period-cohort Poisson model to estimate the...

Women and girls aged 15 to 24 years old have decreased cervical cancer incidence and mortality after the introduction of the human papillomavirus (HPV) vaccine, according to a research letter published in JAMA Pediatrics. Tara Tabibi, from the St. Louis University School of Medicine, and colleagues obtained national age-adjusted cervical cancer incidence and mortality data from...

According to a study published in JAMA Oncology, cervical cancer incidence varies significantly between poor and wealthy New York City neighborhoods. Stephanie Cham, M.D., from Brigham and Women’s Hospital/Dana Farber Cancer Institute in Boston, and colleagues quantified the association between neighborhood socioeconomic status (SES) and the incidence of cervical cancer in New York City (2012...